In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

The Emperor of All Maladies reveals the many faces of an iconic, shape-shifting disease that is the defining plague of our generation. The story of cancer is a story of human ingenuity, resilience, and perseverance but also of hubris, arrogance, paternalism, and misperception, all leveraged against a disease that, just three decades ago, was thought to be easily vanquished in an all-out "war against cancer".

When Elon Musk was a kid in South Africa, he was regularly beaten by bullies. One day a group pushed him down some concrete steps and kicked him until his face was a swollen ball of flesh. He was in the hospital for a week. But the physical scars were minor compared to the emotional ones inflicted by his father, an engineer, rogue, and charismatic fantasist.

When Michael Lewis first met him, Sam Bankman-Fried was the world’s youngest billionaire and crypto’s Gatsby. CEOs, celebrities, and leaders of small countries all vied for his time and cash after he catapulted, practically overnight, onto the Forbes billionaire list. Who was this rumpled guy in cargo shorts and limp white socks, whose eyes twitched across Zoom meetings as he played video games on the side?

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

Beginning with opium, the “joy plant,” which has been used for 10,000 years, Thomas Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book.

From the author of The Emperor of All Maladies, winner of the Pulitzer Prize, and The Gene, a #1 New York Times bestseller, comes his most spectacular book yet, an exploration of medicine and our radical new ability to manipulate cells. Rich with Mukherjee’s revelatory and exhilarating stories of scientists, doctors, and the patients whose lives may be saved by their work, The Song of the Cell is the third book in this extraordinary writer’s exploration of what it means to be human.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made “the impossible possible”—creating, testing, and manufacturing a safe and effective COVID-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer overcame a series of crises that were compounded by social and political unrest.

The bestselling author of Leonardo da Vinci and Steve Jobs returns with a “compelling” (The Washington Post) account of how Nobel Prize winner Jennifer Doudna and her colleagues launched a revolution that will allow us to cure diseases, fend off viruses, and have healthier babies.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion.

Ray Dalio does not want you to listen to this audiobook. Late last year, when the billionaire founder of Bridgewater Associates, the largest hedge fund on the planet, announced that he was stepping down from the company he started out of his apartment nearly 50 years ago, the news made headlines around the world. Dalio cultivated an aura of international admiration and fame thanks to his company’s eye-popping success, coupled with a mystique he encouraged with frequent media appearances, celebrity hobnobbing, and his bestselling book, Principles.

You wake up and feel a tickle in your throat. Your head hurts. You’re mildly annoyed as you get the kids ready for school and dress for work yourself. Meanwhile, an epic war is being fought, just below your skin. Millions are fighting and dying for you to be able to complain as you head out the door. So what, exactly, is your immune system? In Immune, Philipp Dettmer, the brains behind the most popular science channel on YouTube, takes listeners on a journey through the fortress of the human body and its defenses.

From an award-winning Fortune reporter, an explosive narrative investigation of the generic drug boom that reveals the life-threatening dangers posed by globalization - The Jungle for pharmaceuticals.

In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

Lee Hood did that rarest of things. He enabled scientists to see things they couldn't see before and do things they hadn't dreamed of doing. Scientists can now sequence complete human genomes in a day, setting in motion a revolution that is personalizing medicine. Hood, a son of the American West, was an unlikely candidate to transform biology. But with ferocious drive, he led a team at Caltech that developed the automated DNA sequencer, the tool that paved the way for the Human Genome Project.

Salk became a cultural hero and icon for a whole generation. Now, at the fiftieth anniversary of the first national vaccination program, and as humanity is tantalizingly close to eradicating polio worldwide, comes this unforgettable chronicle. Salk's work was an unparalleled achievement, and it makes for a magnificent listen.

This comprehensive and gripping narrative, which received the 2006 Pulitzer Prize for history, covers all the challenges, characters, and controversies in America's relentless struggle against polio. Funded by philanthropy and grassroots contributions, Salk's killed-virus vaccine (1954) and Sabin's live-virus vaccine (1961) began to eradicate this dreaded disease.

A riveting, powerful telling of the story of the grassroots movement of activists, many of them in a life-or-death struggle, who seized upon scientific research to help develop the drugs that turned HIV from a mostly fatal infection to a manageable disease. Ignored by public officials, religious leaders, and the nation at large, and confronted with shame and hatred, this small group of men and women chose to fight for their right to live by educating themselves and demanding to become full partners in the race for effective treatments.

American taxpayers spend $30 billion annually funding biomedical research, but over half of these studies can't be replicated due to poor experimental design, improper methods, and sloppy statistics. Bad science doesn't just hold back medical progress, it can sign the equivalent of a death sentence for terminal patients. In Rigor Mortis, Richard Harris explores these urgent issues with vivid anecdotes, personal stories, and interviews with the top biomedical researchers. We need to fix our dysfunctional biomedical system - before it's too late.

The Nazis discovered it. The Allies won the war with it. It conquered diseases, changed laws, and single-handedly launched the era of antibiotics. This incredible discovery was sulfa, the first antibiotic medication. In The Demon Under the Microscope, Thomas Hager chronicles the dramatic history of the drug that shaped modern medicine.

It's not fiction: Gary Lynch is the real thing, the epitome of the rebel scientist - malnourished, contentious, inspiring, explosive, remarkably ambitious, consistently brilliant. He is one of the foremost figures of contemporary neuroscience, and his decades-long quest to understand the inner workings of the brain's memory machine has begun to pay off.

Few were ready when a mysterious respiratory illness emerged in Wuhan, China, in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world’s biggest drug and vaccine makers were slow to react or couldn’t muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization.

In 2013, the New York Times published an obituary for Yvonne Brill. It began: “She made a mean beef stroganoff, followed her husband from job to job, and took eight years off from work to raise three children.” It wasn’t until the second paragraph that readers discovered why the Times had devoted several hundred words to her life: Brill was a brilliant rocket scientist who invented a propulsion system to keep communications satellites in orbit, and had recently been awarded the National Medal of Technology and Innovation.

American technological prowess used to be unrivaled. But because of globalization, and with the blessing of the US government, once proprietary materials, components, and technologies are increasingly commercialized outside the United States. Nowhere is this more dangerous than in China's monopoly of rare earth elements - materials that are essential for nearly all modern consumer goods, gadgets, and weapons systems.

No Better Time tells of a young, driven mathematical genius who wrote a set of algorithms that would create a faster, better Internet. It's the story of a beautiful friendship between a loud, irreverent student and his soft-spoken MIT professor, of a husband and father who spent years struggling to make ends meet only to become a billionaire almost overnight with the success of Akamai Technologies, the Internet content delivery network he cofounded with his mentor.

Since the 1930s, the scale of scientific endeavors has grown exponentially. The birth of Big Science can be traced to Berkeley, California, nearly nine decades ago, when a resourceful young scientist pondered his new invention and declared, "I'm going to be famous!" Ernest Orlando Lawrence's cyclotron would revolutionize nuclear physics, but that was only the beginning of its impact.This is the incredible story of how one invention changed the world and of the man principally responsible for it all. Michael Hiltzik tells the riveting full story here for the first time.

Ori Brafman and management consultant Judah Pollack dramatically demonstrate how even the best and most efficient organizations - from Fortune 500 companies to today's US Army - can become more innovative by allowing a little unstructured space and "contained chaos" into their planning and decision-making. Through their consulting work, they realized that while structure and hierarchy are essential both in large corporations and small groups, too much of either can stifle creativity.

We know it simply as "the pill", yet its genesis was anything but simple. Jonathan Eig's masterful narrative revolves around four principal characters: the fiery feminist Margaret Sanger, who was a champion of birth control in her campaign for the rights of women but neglected her own children in pursuit of free love; the beautiful Katharine McCormick, who owed her fortune to her wealthy husband, the son of the founder of International Harvester and a schizophrenic.

In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

The search to find medicines is as old as disease, which is to say as old as the human race. Through serendipity - by chewing, brewing, and snorting - some Neolithic souls discovered opium, alcohol, snakeroot, juniper, frankincense, and other helpful substances. Ötzi the Iceman, the 5,000-year-old hunter frozen in the Italian Alps, was found to have whipworms in his intestines and Bronze Age medicine, a worm-killing birch fungus, knotted to his leggings.

In Regenesis, George Church and science writer Ed Regis explore the possibilities of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. These technologies - far from the out-of-control nightmare depicted in science fiction - have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span.

On a moonless night in January 1991, a dozen US aircraft appeared in the skies over Baghdad. To the Iraqi air defenses, the planes seemed to come from nowhere. Each aircraft was more than 60 feet in length and with a wingspan of 40 feet, yet its radar footprint was the size of a ball bearing. Here was the first extensive combat application of Stealth technology. And it was devastating.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made “the impossible possible”—creating, testing, and manufacturing a safe and effective COVID-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer overcame a series of crises that were compounded by social and political unrest.

Futurists insist that AI will soon eclipse the capacities of the most gifted human mind. What hope do we have against superintelligent machines? But we aren't really on the path to developing intelligent machines. In fact, we don't even know where that path might be. Erik Larson takes us on a tour of the landscape of AI to show how far we are from superintelligence and what it would take to get there.

Information architecture (IA) is far more challenging - and necessary - than ever. To guide you through this broad ecosystem, this popular guide - now in its fourth edition - provides essential concepts, methods, and techniques for digital design that have withstood the test of time. UX designers, product managers, developers, and anyone involved in digital design will learn how to create semantic structures that will help people engage with your message.